Senior Chinese health official admits Chinese vaccines ‘don’t have very high protection rates’


In an unprecedented move, the Director of the China Centers for Disease Control Gao Fu admitted that Chinese vaccines “don’t have very high protection rates.” The health official was speaking at a conference on Saturday in Chengdu, a city in southwestern China.


Gao also that the country was formally considering whether they should use different vaccines from different technical lines for the process of immunization.


On Sunday, at a news conference, officials did not respond when asked about Gao’s comment or whether there has been an official change in plans. A CDC official mentioned that developers were working on mRNA vaccines.


The official, Wang Huaqing said that that the mRNA vaccines developed in China had “entered the clinical trial stage” but no timeline for use was mentioned by him.


Earlier, China had distributed several millions of Sinovac vaccines to Brazil, Mexico, Turkey, Indonesia and more. Beijing was looking to undermine the Pfizer-BioNTech vaccine while promoting the effectiveness of its indigenous Sinovac vaccine


However, Sinovac has efficiency as low as 50.4 percent in preventing symptomatic infections according to researchers in Brazil. The threshold at which a vaccine is considered useful by health experts is 50 percent. The Pfizer-BioNTech vaccine has an efficacy rate of 97 percent.


A Sinovac spokesman Liu Peicheng said that varying levels of effectiveness have been seen but he attributed this to different factors such as age of people in a study, the virus strain and other reasons.


Earlier Gao, Chinese media and health and science blogs in China had questioned both the safety and the efficacy of the Pfizer vaccine. Now, Beijing is conducting research and clinical trials, using the same type of vaccine – mRNA that Pfizer and Moderna used to develop their efficient vaccines.


Experts say mixing vaccines might increase effectiveness. British researchers are experimenting on a combination of the traditional AstraZeneca vaccine and the new mRNA Pfizer-BioNtech vaccine to check whether this vaccine is more effective.

Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer